Walleye Capital LLC Lowers Position in Rezolute, Inc. $RZLT

Walleye Capital LLC lowered its position in Rezolute, Inc. (NASDAQ:RZLT) by 93.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 33,605 shares of the company’s stock after selling 457,861 shares during the period. Walleye Capital LLC’s holdings in Rezolute were worth $97,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of RZLT. Woodline Partners LP increased its stake in Rezolute by 2,817.1% in the 4th quarter. Woodline Partners LP now owns 1,089,345 shares of the company’s stock worth $5,338,000 after buying an additional 1,052,002 shares in the last quarter. Integral Health Asset Management LLC increased its stake in Rezolute by 100.0% in the 4th quarter. Integral Health Asset Management LLC now owns 500,000 shares of the company’s stock worth $2,450,000 after buying an additional 250,000 shares in the last quarter. J. Goldman & Co LP purchased a new stake in Rezolute in the 4th quarter worth $1,140,000. Point72 Europe London LLP purchased a new stake in Rezolute in the 4th quarter worth $720,000. Finally, Dimensional Fund Advisors LP increased its stake in Rezolute by 222.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 185,768 shares of the company’s stock worth $910,000 after buying an additional 128,190 shares in the last quarter. Hedge funds and other institutional investors own 82.97% of the company’s stock.

Rezolute Stock Up 8.4%

RZLT opened at $8.00 on Friday. The firm has a 50-day simple moving average of $6.03 and a two-hundred day simple moving average of $4.49. Rezolute, Inc. has a 52 week low of $2.21 and a 52 week high of $8.06. The company has a market capitalization of $696 million, a PE ratio of -6.96 and a beta of 0.03.

Insider Activity at Rezolute

In related news, Director Young-Jin Kim acquired 1,230,769 shares of the company’s stock in a transaction on Friday, June 13th. The stock was acquired at an average price of $3.25 per share, with a total value of $3,999,999.25. Following the acquisition, the director directly owned 8,423,386 shares of the company’s stock, valued at approximately $27,376,004.50. This trade represents a 17.11% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Over the last ninety days, insiders have bought 1,241,345 shares of company stock worth $4,041,196. 18.39% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on RZLT. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Wedbush reiterated an “outperform” rating and issued a $12.00 price target on shares of Rezolute in a research note on Wednesday, May 14th. Finally, HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Rezolute in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, Rezolute currently has a consensus rating of “Buy” and a consensus target price of $12.50.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.